Albumedix, Cobra partner on viral vector manufacturing

By The Science Advisory Board staff writers

April 28, 2021 -- Albumedix and Cobra Biologics, the gene therapy division of Cognate BioServices, will collaborate on viral vector manufacturing.

The companies will focus on upstream and downstream process optimization and stability enhancement in scale-up manufacturing of adeno-associated viruses and lentiviral vectors through proprietary recombinant human albumin-based product from Albumedix.

Financial details of the collaboration were not disclosed.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.